Jade Biosciences, Inc.
NASDAQ:JBIO · NASDAQ Global Market
-$0.21 today
Vol 3.28M · Avg 0.83M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-38.3%
avg -96.5%
ROIC
-34.1%
avg -93.7%
ROA
-36.4%
avg -72.9%
Analysis
ROIC is currently the strongest return metric at -34.1% versus its period average of -93.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Tom Frohlich | President, CEO & Director | $1.02M | — | 50 | $472,500.00 | 1.45% |
Andrew James King | President of Research & Development | $765,901.00 | — | 46 | $386,113.00 | 1.18% |
Bradford D. Dahms | CFO & Treasurer | $350,051.00 | — | 37 | $226,875.00 | 0.70% |
Valerie Fauvelle | Senior Vice President of Regulatory & Quality | — | — | — | — | — |
Jason Wright | Senior Vice President of Chemistry, Manufacturing & Controls | — | — | — | — | — |
Jonathan Quick | Senior Vice President of Finance | — | — | — | $0.00 | <0.01% |
Amy Sullivan | Senior Vice President of Development Operations | — | — | — | — | — |
Lori Stewart | Senior Vice President of People | — | — | — | — | — |
Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy | — | — | — | — | — |
Edward R. Conner | Chief Medical Officer | — | — | 53 | — | — |
Elizabeth Balta | Chief Legal Officer & Corporate Secretary | — | — | 55 | $168,750.00 | 0.52% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Tectonic Therapeutic, Inc.
NASDAQ:TECX
$561.74M
XOMA Royalty Corp.
NASDAQ:XOMA
$525.59M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$440.41M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$351.21M
Silence Therapeutics plc
NASDAQ:SLN
$324.97M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$296.11M
AC Immune S.A.
NASDAQ:ACIU
$240.69M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$117.02M
Genelux Corporation
NASDAQ:GNLX
$109.47M
Who manages JBIO?
Jade Biosciences, Inc. (JBIO) lists 11 active executives. The top listed executive is Valerie Fauvelle, Senior Vice President of Regulatory & Quality.
Are JBIO insiders buying or selling?
Recent insider activity shows net buying of $37.30M.
Explore More
Continue the stock analysis
Jump to another research area for this company.